Key Drivers
- High margins
- Robust FCF
- Rich multiples
AIAI Summary
Stryker's valuation now hinges on its ability to execute a costly pivot from device seller to robotics‑and‑digital platform—if Mako RPS/SmartHospital adoption, international regulatory rollouts, and service/consumable attach rates scale (track installations, procedure volumes, and margin mix) the premium is justified, but any supply‑chain, cybersecurity or commercialization slip will likely trigger sharp multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Robust FCF
- •Rich multiples
Stryker delivers strong margins, ROIC and free cash flow with healthy liquidity and manageable leverage, but richly priced multiples and large intangibles reduce margin for upside.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Support at $336–$338
- •Resistance near SMA
SYK has pulled back about 13% over the last month to ~$335.67, trading ~8% below the last-month SMA (~$364.60) and resting on $336–$338 support, while a sustained move back above the $360–$388 resistance/SMA would signal a reversal.
Sharp ~13% decline from ~$387.46 to ~$335.67 over the last month indicating elevated short-term downside risk
Sentiment & News
Key News Insights:
- •Product innovation
- •Cyberattack disruption
- •Mixed investor flows
Stryker's new Triathlon implants, expanded robotics and SmartHospital platform signal strong product-led growth but a major March cyberattack that disrupted operations and mixed institutional trading have created near-term execution and valuation risks.
Continued product and digital momentum supports long‑term robotics growth, but operational disruption and diverging investor sentiment heighten short‑term execution and valuation risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings